^
    3d
    Descartes-25 in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=9, Terminated, Cartesian Therapeutics | Active, not recruiting --> Terminated; Phase 1 enrollment completed. Further clinical development terminated.
    Trial termination
    9d
    Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide (ASH 2024)
    P1 | "Tal-DP exhibits a deep, long-term impact on efficacy through complementary mechanisms of action and may be especially beneficial in pts with prior BsAb exposure, who typically have unfavorable BL immune profiles. Ongoing analyses of tec-DP from MajesTEC-2 (NCT04722146) will be presented."
    PK/PD data • Clinical
    |
    Darzalex (daratumumab) • pomalidomide • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    11d
    A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) (clinicaltrials.gov)
    P1/2, N=111, Recruiting, Sanofi | Trial primary completion date: Apr 2026 --> Mar 2027
    Trial primary completion date
    |
    SAR445514
    14d
    A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=186, Not yet recruiting, Regeneron Pharmaceuticals
    New P1/2 trial
    |
    linvoseltamab (REGN5458)
    14d
    MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM (clinicaltrials.gov)
    P2, N=300, Recruiting, Multiple Myeloma Research Consortium | Not yet recruiting --> Recruiting | Initiation date: Jul 2024 --> Nov 2024
    Enrollment open • Trial initiation date
    |
    Tecvayli (teclistamab-cqyv)
    17d
    MajesTEC-9: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=650, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Oct 2025 --> Feb 2026
    Trial primary completion date
    |
    CD38 positive
    |
    lenalidomide • bortezomib • carfilzomib • dexamethasone • pomalidomide • Tecvayli (teclistamab-cqyv)
    23d
    GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (clinicaltrials.gov)
    P2, N=130, Recruiting, University of Heidelberg Medical Center | N=70 --> 130 | Trial completion date: Oct 2027 --> Aug 2028 | Trial primary completion date: Oct 2026 --> Feb 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    24d
    Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance (clinicaltrials.gov)
    P2, N=65, Not yet recruiting, Washington University School of Medicine | Trial completion date: Sep 2031 --> Dec 2031 | Initiation date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2031 --> Dec 2031
    Trial completion date • Trial initiation date • Trial primary completion date • Post-transplantation
    |
    clonoSEQ
    |
    Elrexfio (elranatamab-bcmm)
    25d
    A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=156, Active, not recruiting, Celgene | Phase classification: P1/2 --> P1 | Trial primary completion date: Aug 2025 --> May 2025
    Phase classification • Trial primary completion date • Combination therapy
    |
    dexamethasone • alnuctamab (CC-93269) • mezigdomide (CC-92480)
    25d
    LMY-920-003: BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Luminary Therapeutics | Initiation date: Jun 2024 --> Jan 2025 | Trial primary completion date: Oct 2025 --> Jan 2026
    Trial initiation date • Trial primary completion date • CAR T-Cell Therapy
    25d
    A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=174, Terminated, Amgen | Phase classification: P1/2 --> P1
    Phase classification • Combination therapy
    |
    pomalidomide • pavurutamab (AMG 701) • dexamethasone injection
    25d
    A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, European Myeloma Network B.V.
    New P2 trial
    |
    Tecvayli (teclistamab-cqyv)
    28d
    EMBRACE: Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Ontario Clinical Oncology Group (OCOG) | Initiation date: Jul 2024 --> Nov 2024
    Trial initiation date • IO biomarker
    |
    Elrexfio (elranatamab-bcmm)
    1m
    Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (HPN217) (clinicaltrials.gov)
    P1, N=100, Active, not recruiting, Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial primary completion date
    |
    podentamig (MK-4002)
    1m
    A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=48, Recruiting, Keymed Biosciences Co.Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    Long-term follow-up of the phase 1/2 MajesTEC-1 study of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM) (DGHO 2024)
    "With the longest follow-up of any BsAb in MM, tec continues to demonstrate deep and durable responses, including in pts switching to less frequent dosing. The tec safety profile remains consistent with BCMA-targeted BsAb, with a notable decrease in new-onset severe infections with time."
    P1/2 data • Clinical
    |
    Tecvayli (teclistamab-cqyv)
    1m
    MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=761, Recruiting, Pfizer | Active, not recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • dexamethasone • pomalidomide • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1m
    TRIMM-3: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=74, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Sep 2024 --> Feb 2025
    Trial primary completion date • Combination therapy • Checkpoint inhibition
    |
    Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    1m
    Compassionate Use of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Who Have Been Previously Treated With Linvoseltamab and Background Dupilumab (clinicaltrials.gov)
    P=N/A, N=0, Temporarily Not Available, Regeneron Pharmaceuticals
    New trial
    |
    Dupixent (dupilumab) • linvoseltamab (REGN5458)
    1m
    A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies (clinicaltrials.gov)
    P=N/A, N=1, Active, not recruiting, Pfizer | N=700 --> 1
    Enrollment change
    |
    Elrexfio (elranatamab-bcmm)
    2ms
    Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use. (clinicaltrials.gov)
    P=N/A, N=1, Active, not recruiting, Pfizer | Not yet recruiting --> Active, not recruiting | N=430 --> 1
    Enrollment closed • Enrollment change
    |
    Elrexfio (elranatamab-bcmm)
    2ms
    MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=4, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    Elrexfio (elranatamab-bcmm)
    2ms
    A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis (clinicaltrials.gov)
    P1, N=180, Recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trispecific
    |
    JNJ-5322
    2ms
    MajesTEC-1: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=302, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Tecvayli (teclistamab-cqyv)
    2ms
    A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, Pfizer | Phase classification: P2 --> P1/2
    Phase classification • Immunomodulating
    |
    Elrexfio (elranatamab-bcmm)
    2ms
    A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=180, Recruiting, TeneoOne Inc. | N=120 --> 180 | Trial completion date: Jul 2026 --> Mar 2027 | Trial primary completion date: Jul 2026 --> Mar 2027
    Enrollment change • Trial completion date • Trial primary completion date • Adverse events
    |
    ABBV-383 IV
    2ms
    MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=761, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • pomalidomide • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies (clinicaltrials.gov)
    P=N/A, N=700, Active, not recruiting, Pfizer
    New trial • HEOR • Real-world evidence • Real-world
    |
    Elrexfio (elranatamab-bcmm)
    2ms
    ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, University of Washington
    New P1 trial
    |
    Tecvayli (teclistamab-cqyv) • vevoctadekin (ST-067)
    2ms
    Korean Post Marketing Surveillance for ELREXFIO (Elranatamab). (clinicaltrials.gov)
    P=N/A, N=150, Not yet recruiting, Pfizer
    New trial
    |
    Elrexfio (elranatamab-bcmm)
    3ms
    Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) (SOHO 2024)
    P1, P2 | "With the longest follow-up of any BsAb in MM, teclistamab continues to demonstrate deep and durable responses, including in patients who switch to less frequent dosing. The teclistamab safety profile remains consistent with that of BCMA-targeted bispecific therapies, with a notable decrease in new onset of severe infections with time."
    P1/2 data • Clinical
    |
    Tecvayli (teclistamab-cqyv)
    3ms
    A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=116, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting | Initiation date: Feb 2024 --> Jul 2024
    Enrollment open • Trial initiation date
    3ms
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=70, Recruiting, Excyte Biopharma Ltd
    New P1 trial
    3ms
    Plan Development for Giving Teclistamab in the Outpatient Setting (clinicaltrials.gov)
    P4, N=15, Not yet recruiting, University Health Network, Toronto | Initiation date: Apr 2024 --> Oct 2024
    Trial initiation date
    |
    Actemra IV (tocilizumab) • Tecvayli (teclistamab-cqyv)
    3ms
    Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis (clinicaltrials.gov)
    P1/2, N=49, Not yet recruiting, Brigham and Women's Hospital
    New P1/2 trial
    |
    Elrexfio (elranatamab-bcmm)
    3ms
    GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=116, Recruiting, Genrix (Shanghai) Biopharmaceutical Co., Ltd.
    New P2 trial
    3ms
    A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=156, Active, not recruiting, Celgene | Trial completion date: Feb 2032 --> Aug 2025 | Trial primary completion date: Feb 2032 --> Aug 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    dexamethasone • alnuctamab (CC-93269) • mezigdomide (CC-92480)
    3ms
    MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=90, Recruiting, Pfizer | Trial completion date: Mar 2028 --> Nov 2027 | Trial primary completion date: May 2026 --> Dec 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    carfilzomib • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
    3ms
    OPTec: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (clinicaltrials.gov)
    P2, N=75, Recruiting, SCRI Development Innovations, LLC | N=50 --> 75
    Enrollment change
    |
    Actemra IV (tocilizumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    3ms
    TRIMM-3: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=74, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=152 --> 74
    Enrollment closed • Enrollment change • Combination therapy • Checkpoint inhibition
    |
    Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    3ms
    Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (HPN217) (clinicaltrials.gov)
    P1, N=100, Active, not recruiting, Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Trial completion date: May 2025 --> Nov 2025
    Trial completion date
    |
    podentamig (MK-4002)
    3ms
    A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) (clinicaltrials.gov)
    P1/2, N=111, Recruiting, Sanofi | Trial completion date: Aug 2027 --> Mar 2028
    Trial completion date
    |
    SAR445514